Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands

被引:10
作者
Oosterheert, JJ
Bonten, MJM
Schneider, MME
Hoepelman, IM
机构
[1] Univ Med Ctr, Dept Internal Med & Infect Dis, Div Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr, Eijkman Winkler Inst Infect Dis Microbiol & Infla, NL-3508 GA Utrecht, Netherlands
[3] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
关键词
antibiotic use; community-acquired pneumonia; fluoroquinolones; guidelines; macrolides;
D O I
10.1111/j.1469-0691.2005.01286.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study evaluated the possible changes in antibiotic use that might follow the implementation of British or North American guidelines for the treatment of community-acquired pneumonia (CAP) in The Netherlands. Patients admitted for mild, moderate and severe CAP were evaluated prospectively. Volume of antibiotic use, based upon guidelines of the British Thoracic Society (BTS), the Infectious Diseases Society of America (IDSA) or the American Thoracic Society (ATS), was estimated and compared to current practice. For 248 patients, current antibiotic use was 3087 defined daily doses. Antibiotic use would increase by 38% if based on ATS guidelines, by 23% if based on IDSA guidelines, and by 21% if based on BTS guidelines. The most significant increase in antibiotic use would occur for cases of moderate CAP, with incremental antibiotic costs of 1 750 000-3 500 000 Euros in The Netherlands.
引用
收藏
页码:992 / 998
页数:7
相关论文
共 46 条
[1]   Community-acquired pneumonia in adults: Guidelines for management [J].
Bartlett, JG ;
Breiman, RF ;
Mandell, LA ;
File, TM .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838
[2]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[3]   EVALUATION OF URINARY ANTIGEN ELISA FOR DIAGNOSING LEGIONELLA PNEUMOPHILA SEROGROUP-1 INFECTION [J].
BIRTLES, RJ ;
HARRISON, TG ;
SAMUEL, D ;
TAYLOR, AG .
JOURNAL OF CLINICAL PATHOLOGY, 1990, 43 (08) :685-690
[4]   Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia [J].
Burgess, DS ;
Lewis, JS .
CLINICAL THERAPEUTICS, 2000, 22 (07) :872-878
[5]   EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF RESPIRATORY-TRACT INFECTIONS [J].
CHOW, AW ;
HALL, CB ;
KLEIN, JO ;
KAMMER, RB ;
MEYER, RD ;
REMINGTON, JS .
CLINICAL INFECTIOUS DISEASES, 1992, 15 :S62-S88
[6]   Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].
Davidson, R ;
Cavalcanti, R ;
Brunton, JL ;
Bast, DJ ;
de Azavedo, JCS ;
Kibsey, P ;
Fleming, C ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750
[7]   Evaluation of binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients [J].
Dowell, SF ;
Garman, RL ;
Liu, G ;
Levine, OS ;
Yang, YH .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) :824-825
[8]   PREDICTION OF MICROBIAL ETIOLOGY AT ADMISSION TO HOSPITAL FOR PNEUMONIA FROM THE PRESENTING CLINICAL-FEATURES [J].
FARR, BM ;
KAISER, DL ;
HARRISON, BDW ;
CONNOLLY, CK .
THORAX, 1989, 44 (12) :1031-1035
[9]  
FINCH R, 1993, BRIT J HOSP MED, V49, P346
[10]   Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: Results from the United States community-acquired pneumonia project [J].
Frei, CR ;
Koeller, JM ;
Burgess, DS ;
Talbert, RL ;
Johnsrud, MT .
PHARMACOTHERAPY, 2003, 23 (09) :1167-1174